SOMERSET, N.J., May 21, 2013 /PRNewswire/ -- Terumo Medical
Corporation (Terumo), today announced that it was pleased with the
U.S. District Court for the District of New Jersey's Order approving an agreement of
the parties under which Vascular Solutions Inc. will cease further
manufacture, sales, and distribution of its R-Band™ Radial
Hemostasis Device, pending litigation of Terumo's claims.
In February, Terumo filed a patent infringement lawsuit alleging
that the R Band™ Radial Hemostasis Device infringes on U.S. patent
and trademark rights held by Terumo Medical Corporation for its
proprietary TR Band™ Radial Compression Device. The R-Band is
distributed in the U.S. by Vascular Solutions and manufactured by
Lepu Medical Technology. Terumo sought an injunction against
further sales of the infringing product.
"Terumo is extremely gratified with the Court's Order. We are
thankful for the opportunity to successfully defend our TR Band™
device, which is a critical part of our transradial solutions
portfolio," said James Rushworth,
President, Terumo Interventional Systems and Onset Medical
Corporation. "As a market leader, Terumo is committed to doing what
is right for our business and, when appropriate, we will vigorously
protect our investments, assets and intellectual property."
Terumo's market-leading TR Band™ Radial Compression Device is
used to achieve patent hemostasis immediately following a
transradial access diagnostic and intervention in the treatment of
cardiac and vascular disease. The clear band is placed around the
patient's wrist to effectively stop access-point bleeding. The TR
Band™ features dual compression balloons that maintain precise
pressure on the radial artery to ensure blood return without
compromising local nerve structure. Transradial access
interventions have been shown to significantly reduce bleeding
complications by up to 75 percent when compared to femoral (through
the groin) interventions.
Terumo Interventional Systems
Terumo Interventional
Systems (TIS) is a strategic business unit of Terumo Medical
Corporation. As a market leader in entry site management and lesion
access, TIS is committed to pursuing unique technologies designed
to enhance treatment of coronary and peripheral endovascular
diseases as well as driving strategic initiatives focused on
Critical Limb Ischemia, Complex Coronary Intervention and
Transradial Access. Terumo® Urology, a dedicated group within TIS,
focuses on direct sales, marketing, support and distribution of key
products to the urological specialty.
TIS directly markets a full line of guidewires, catheters,
introducer sheaths, guiding sheaths and embolization products for
use in a multitude of different interventional procedures.
Terumo Medical Corporation
Founded in 1972 as a Terumo
Corporation subsidiary, Terumo Medical Corporation (TMC) develops,
manufactures, and markets a complete, solutions-based portfolio of
high-quality medical devices used in a broad range of applications
for numerous areas of the healthcare industry. TMC is
comprised of two business divisions: Terumo Interventional
Systems and Terumo Medical Products. The company places a premium
on providing customers with world-class products, training and
education programs that drive clear economic value, better clinical
outcomes and improved Quality of Life for patients.
Terumo Corporation
Tokyo-based Terumo Corporation is one of the
world's leading medical device manufacturers with $5 billion in sales and operations in more than
160 nations. Founded in 1921, the company develops, manufactures,
and distributes world-class medical devices including products for
use in cardiothoracic surgery, interventional procedures, and
transfusion medicine; the company also manufactures a broad array
of syringe and hypodermic needle products for hospital and
physician office use. Terumo contributes to society by providing
valued products and services to the healthcare market and by
responding to the needs of healthcare providers and the people they
serve.
Terumo Corporation's shares are listed on the first section of
the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>,
or Bloomberg 4543: JP) and is a component of the Nikkei 225,
Japan's leading stock index.
SOURCE Terumo Medical Corporation
